Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases with limited treatment options.
• Aberrant protein aggregation and dysfunction are key pathological hallmarks in both ALS and FTD.

Purpose of the Study:

• To review emerging small-molecule therapeutic strategies for ALS and FTD.
• To critically assess the current landscape of small-molecule drug development for these conditions.

Main Methods:

• Literature review of recent research on small-molecule interventions for ALS and FTD.
• Analysis of therapeutic targets including phase separation, RNA-protein interactions, TDP-43, PARP, C9ORF72 repeat expansions, and autophagy.

Main Results:

• Several small-molecule approaches are under investigation, targeting diverse molecular pathways implicated in ALS and FTD pathogenesis.
• Key strategies include modulating liquid-liquid phase separation, inhibiting TDP-43 phosphorylation, and targeting C9ORF72 repeat expansions.

Conclusions:

• Emerging small molecules offer potential new therapeutic avenues for ALS and FTD.
• Significant challenges remain in translating these preclinical findings into effective clinical treatments.